Physician
Pathway Healthcare- Columbus, MS LLC
Pathway Healthcare- Columbus, MS LLC was paid $212K by Medicaid between Aug 2018 and Jun 2024, across 10 billing codes. Its largest line is G2087, Office-based treatment for opioid use disorder, including care coordination, individual therapy and group therapy and counseling; at least 60 minutes in a subsequent calendar month — 43% of everything it billed.
33Billing provider infoPATHWAY HEALTHCARE- COLUMBUS, MS LLC
COLUMBUS, MS 39705
COLUMBUS, MS 39705
33aNPI1245755990assigned 08/03/2017
33bProvider typeAddiction Medicine (Family Medicine) Physician
28Total paid$212K
24GClaims6,145
24DCodes billed10
24AFirst – last monthAug 2018 – Jun 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 328 | $0.00 | |
| 2019 | 1,342 | $0.00 | |
| 2022 | 814 | $10K | |
| 2023 | 2,289 | $108K | |
| 2024incomplete | 1,372 | $94K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G2087 | Office-based treatment for opioid use disorder, including care coordination, individual therapy and group therapy and counseling; at least 60 minutes in a subsequent calendar month | 43% | 525 | 443 | $90K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 39% | 1,885 | 1,081 | $82K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 11% | 562 | 444 | $24K |
| 80305 | 3.8% | 1,866 | 1,058 | $8K | |
| 99406 | 2.9% | 936 | 587 | $6K | |
| 99401 | <1% | 178 | 125 | $933.16 | |
| 81025 | <1% | 58 | 49 | $401.46 | |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | 0% | 25 | 13 | $0.00 |
| 99484 | 0% | 96 | 89 | $0.00 | |
| 99407 | 0% | 14 | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSPENCER, KRYSTAL (BUSINESS OFFICE MANAGER)